Multiple Myeloma Coverage from Every Angle

Novel Antibody-Drug Conjugate in Resistant Multiple Myeloma

By: Cordi Craig
Posted: Thursday, March 21, 2019

Patients with relapsed or refractory multiple myeloma did not seem to respond to DFRF4539A, an anti-FcRH5 antibody-drug conjugate to the antimitotic agent monomethyl auristatin E, according to a phase I trial published in Blood Cancer Journal. Although A. Keith Stewart, MB, CHB, of Mayo Clinic, Phoenix, and colleagues concluded that the treatment was unsuccessful, FcRH5, a cell-surface marker enriched on diseased plasma cells versus normal tissues or other hematologic malignancies, remains a valid myeloma target.

“Drugs with other mechanisms of action, including T-cell directing, bispecific antibodies, or chimeric antigen receptor–modified T cells, may prove beneficial to multiple myeloma patients in the future, when directed against FcRH5,” the authors concluded.

DFRF4539A was given intravenously to 39 patients. Two dosage regimens were assessed: 0.3 to 2.4 mg/kg every 3 weeks and 0.8 to 1.1 mg/kg weekly.

Overall, the authors observed 37 adverse events (95%), 8 serious adverse events (21%), and 15 grade 3 or higher adverse events (39%). The most common treatment-related adverse event was anemia (n = 10). No deaths were reported, although 2 patients reported grade 3 acute renal failure. The maximum tolerated dose was not reached.

At the tested dosage regimens, the authors observed limited activity. Partial response, minimal response, and stable disease were observed in 2 patients (5%), 1 patient (3%), and 18 patients (46%), respectively. Progressive disease was reported in 16 patients (41%). Although patients did not respond to treatment, the authors confirmed the expression and presence of FcRH5.

Disclosure: The study authors’ disclosure information can be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.